We manufacture clinical-grade pluripotent stem cells
The potential of cell therapies for hard-to-treat conditions has been limited by the complex and costly logistics of autologous treatments. Therapy cells are produced “from the patient, for the patient.”
Off-the-shelf, allogenic approaches – where treatments are manufactured from a healthy donor’s cells and used for multiple patients – have moved into the spotlight as a way to accelerate time-to-patient and reduce cost significantly. Boosting immune compatibility of donor cells and ensuring their fit for therapeutic purposes is critical to realize such advanced therapy medicinal products.
This is where RHEINCELL excels.
We produce GMP-grade human induced pluripotent stem cells (iPSCs) from a unique source of clinically-approved, donor-consented umbilical cord blood units. Furthermore, we expedite allogenic approaches with a collection of HLA-homozygous iPSCs that reduce transplant rejection. Partnering with innovative developers of off-the-shelf iPSC-based therapies, we advance cell therapies where they begin: at the cell.
what we do
The latest news from RHEINCELL
RHEINCELL IS AT ADVANCED THERAPIES 2021 VIRTUAL
Continuously seeking new partnerships and innovative collaborations, Thomas Marx is attending this year's virtual session of Advanced Therapies Congress & Expo. Cutting-edge talks and insightful discussions packed into 3 high-power days will keep Thomas busy. Make sure to join him.
RHEINCELL WILL BE AT ISSCR 2021 VIRTUAL
Our colleagues Thomas Marx and Dr. Katja Aschermann will be attending this year's virtual ISSCR meeting. As always, the program is an outstanding list of thought leaders, innovation drivers, and world-class researchers. We hope to see you there.
RheinCell teams up with RegMedNet to shine a spotlight on iPSCs
RegMedNet has just announced a new In Focus feature taking a close look at how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. Prepared in collaboration with RheinCell experts, the feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.